Inhibition of RANKL: a new approach to the treatment of osteoporosis.
Doggrell
Sheila A
SA
School of Science, Charles Darwin University, Casuarina, Northern Territory 0811, Australia. sheila.doggrell@cdu.edu.au
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density / Q000187:drug effects; D000069448:Denosumab; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000378:metabolism; D010349:Patient Compliance; D053245:RANK Ligand / Q000276:immunology* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; C505688:TNFSF11 protein, human; D000069448:Denosumab